| 2024年中报 | 2023年年报 | 2023年中报 | 2022年年报 | 2022年中报 | |
|---|---|---|---|---|---|
| 营业收入(元) | |||||
| 非免疫规划疫苗(元) | 1,308,081,995.46 | - | 2,093,506,305.18 | 4,928,637,745.26 | 2,281,179,640.70 |
| 免疫规划疫苗(元) | 58,455,589.45 | - | 63,781,825.01 | 106,445,767.96 | 41,684,148.96 |
| 中间产品(元) | 44,630,793.76 | 17,217,232.62 | 3,003,030.07 | 27,162,085.23 | 13,876,809.73 |
| 技术服务费(元) | 8,474,043.79 | 11,024,348.53 | 4,076,816.71 | 16,552,109.28 | 5,707,593.96 |
| 自主疫苗(元) | - | 4,077,615,026.94 | - | - | - |
| 营业成本(元) | |||||
| 非免疫规划疫苗(元) | 215,549,994.15 | - | 214,955,218.31 | 473,343,502.01 | - |
| 免疫规划疫苗(元) | 45,517,362.82 | - | - | 96,563,724.05 | - |
| 中间产品(元) | 9,837,316.57 | 10,778,357.93 | - | 24,073,154.35 | - |
| 技术服务费(元) | 1,016,317.96 | 7,955,635.93 | - | 9,829,581.04 | - |
| 自主疫苗(元) | - | 571,902,165.53 | - | - | - |
| 毛利(元) | |||||
| 非免疫规划疫苗(元) | 1,092,532,001.31 | - | 1,878,551,086.87 | 4,455,294,243.25 | - |
| 免疫规划疫苗(元) | 12,938,226.63 | - | - | 9,882,043.91 | - |
| 中间产品(元) | 34,793,477.19 | 6,438,874.69 | - | 3,088,930.88 | - |
| 技术服务费(元) | 7,457,725.83 | 3,068,712.60 | - | 6,722,528.24 | - |
| 自主疫苗(元) | - | 3,505,712,861.41 | - | - | - |
| 毛利率(%) | |||||
| 非免疫规划疫苗(%) | 83.52 | - | 89.73 | 90.40 | - |
| 免疫规划疫苗(%) | 22.13 | - | - | 9.28 | - |
| 中间产品(%) | 77.96 | 37.40 | - | 11.37 | - |
| 技术服务费(%) | 88.01 | 27.84 | - | 40.61 | - |
| 自主疫苗(%) | - | 85.97 | - | - | - |
| 收入构成(%) | |||||
| 非免疫规划疫苗(%) | 92.14 | - | 96.73 | 97.04 | 97.38 |
| 免疫规划疫苗(%) | 4.12 | - | 2.95 | 2.10 | 1.78 |
| 中间产品(%) | 3.14 | 0.42 | 0.14 | 0.53 | 0.59 |
| 技术服务费(%) | 0.60 | 0.27 | 0.19 | 0.33 | 0.24 |
| 自主疫苗(%) | - | 99.31 | - | - | - |
| 毛利构成(%) | |||||
| 非免疫规划疫苗(%) | 95.19 | - | 100.00 | 99.56 | - |
| 免疫规划疫苗(%) | 1.13 | - | 0.00 | 0.22 | - |
| 中间产品(%) | 3.03 | 0.18 | 0.00 | 0.07 | - |
| 技术服务费(%) | 0.65 | 0.09 | 0.00 | 0.15 | - |
| 自主疫苗(%) | - | 99.73 | - | - | - |